Exhibit 99.1 Rigel Reports First Quarter 2024 Financial Results and Provides Business Update · First quarter 2024 total revenue of $29.5 million, which includes TAVALISSE net product sales of $21.1 million and REZLIDHIA net product sales of $4.9 million · Expanded Rigel's portfolio with acquisition of GAVRETO, a U.S. marketed product for RET fusion-positive metastatic non-small cell lung cancer and advanced or metastatic thyroid cancer · Appointed Lisa Rojkjaer, M.D. as Chief Medical Officer · Conference ca ...